Back

Study design of the CARDIO-TTRansform cardiac magnetic resonance imaging substudy

1 September 2024 (11:00 - 11:50)
Organised by: Logo
Congress Presentation Part of: Characterisation of cardiomyopathies with cardiac magnetic resonance Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Imaging predictors of adverse prognosis in fabry disease cardiomyopathy: a systematic review and meta-analysis
Mr T. Rojanathagoon (University Of Nottingham, GB)
Abstract Slides Video
Presentation thumbnail
Left atrial strain predicts adverse events in hypertrophic cardiomyopathy: preliminary results from a CMR study
Doctor F. Gonzalez-Santorum (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Comparative assessment of extracellular volume metrics in predicting adverse outcomes in patients with transthyretin amyloid cardiomyopathy
Doctor C. Kronberger (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Myocardial determinants of Functional limitation in advanced Fabry cardiomyopathy
Doctor G. Guida (San Donato Milanese, IT)
Abstract Slides Video
Presentation thumbnail
T2 mapping as a marker of active myocardial injury in Anderson-Fabry disease patients
Doctor M. Schiavo (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Characterisation of cardiomyopathies with cardiac magnetic resonance

The Event

Event poster

ESC Congress 2024

1 September 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
CARDIO-TTRansform trial in ATTR-CM: design and baseline characteristics
thumbnail
Congress Presentation
CMR outcomes following one-time in vivo CRISPR editing with nexiguran ziclumeran in patients with ATTR-CM: phase 1 results
thumbnail
Congress Presentation
Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources